表紙
市場調查報告書
商品編碼
1070526

全球激素避孕藥市場-機會分析和行業預測:按產品、按激素、按年齡組、按最終用戶(2021-2030 年)

Hormonal Contraceptives Market by Product, Hormones, Age Group End User : Global Opportunity Analysis and Industry Forecast, 2021-2030

出版日期: | 出版商: Allied Market Research | 英文 225 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球激素避孕藥市場預計將從 2020 年的 150.2232 億美元增長到 2030 年的 206.7264 億美元,預測期內復合年增長率為 3.3%。

推動全球激素避孕藥具市場增長的主要因素是計劃生育、與少女懷孕相關的健康問題以及對現代避孕方法意識的提高。具有更高功效和更少副作用的激素避孕的進步也在推動市場增長。

本報告對全球激素避孕藥市場進行研究分析,提供市場行情、市場分析、企業概況等系統資訊。

目錄

第 1 章介紹

第 2 章執行摘要

第 3 章市場情況

  • 市場定義和範圍
  • 主要調查結果
    • 主要投資領域
    • 主要成功策略
  • 波特五力分析
    • 供應商的議價能力
    • 新進入者的威脅
    • 替代威脅
    • 競爭對手之間的敵對關係
    • 買家之間的談判權
  • 市場份額分析/主要公司定位
    • 市場份額分析/主要公司定位(2020)
  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
  • COVID-19 影響分析

第 4 章激素避孕藥市場:按產品類型

  • 市場概況
  • 市場規模和預測:按產品類型
  • 口服避孕藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 避孕針
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 緊急避孕藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 陰道環
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 皮膚貼片
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類

第 5 章激素避孕藥市場:按激素

  • 市場概況
  • 市場規模和預測:按激素
  • 孕激素單獨避孕
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 複合激素避孕藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類

第 6 章激素避孕藥市場:按年齡組分類

  • 市場概況
  • 市場規模和預測:按年齡組
  • 24 歲或以下
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 34 歲或以下
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 44 歲或以下
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 44歲以上
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類

第 7 章激素避孕藥市場:按最終用戶分類

  • 市場概況
  • 市場規模和預測:按最終用戶分類
  • 醫院
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 首頁
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 診所
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類

第 8 章激素避孕藥市場:按地區劃分

  • 市場概況
  • 市場規模和預測:按地區
  • 北美
    • 主要市場趨勢和機遇
    • 市場規模和預測:按產品類型
    • 市場規模和預測:按激素
    • 市場規模和預測:按年齡組
    • 市場規模和預測:按最終用戶分類
    • 市場規模和預測:按國家/地區分類
    • 美國激素避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 加拿大激素避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 墨西哥激素避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
  • 歐洲
    • 主要市場趨勢和機遇
    • 市場規模和預測:按產品類型
    • 市場規模和預測:按激素
    • 市場規模和預測:按年齡組
    • 市場規模和預測:按最終用戶分類
    • 市場規模和預測:按國家/地區分類
    • 德國荷爾蒙避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 法國荷爾蒙避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 英國激素避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 義大利荷爾蒙避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 西班牙荷爾蒙避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 其他歐洲激素避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
  • 亞太地區
    • 主要市場趨勢和機遇
    • 市場規模和預測:按產品類型
    • 市場規模和預測:按激素
    • 市場規模和預測:按年齡組
    • 市場規模和預測:按最終用戶分類
    • 市場規模和預測:按國家/地區分類
    • 日本激素避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 中國激素避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 澳大利亞荷爾蒙避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 印度荷爾蒙避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 韓國荷爾蒙避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 其他亞太地區激素避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 市場規模和預測:按產品類型
    • 市場規模和預測:按激素
    • 市場規模和預測:按年齡組
    • 市場規模和預測:按最終用戶分類
    • 市場規模和預測:按國家/地區分類
    • 巴西荷爾蒙避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 南非激素避孕藥市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 沙特阿拉伯的激素避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類
    • 其他拉丁美洲、中東和非洲激素避孕藥具市場
      • 市場規模和預測:按產品類型
      • 市場規模和預測:按激素
      • 市場規模和預測:按年齡組
      • 市場規模和預測:按最終用戶分類

第 9 章公司簡介

  • Pfizer Inc.
  • Ansell Limited
  • Bayer AG
  • Church And Dwight Co. Inc
  • Johnson And Johnson
  • Mayer Laboratories Inc
  • Merck And Co. Inc
  • Mylan N.V
  • Teva Pharmaceutical Industries Ltd
  • The Female Health Company
目錄
Product Code: LI_184574 / A04222

The global hormonal contraceptive market was valued at $ 15,026.23 million in 2020, and is projected to reach $ 20,672.64 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.

Hormonal contraceptives are birth control methods, which act on the endocrine system. These methods include use of hormones that are produced normally by women, such as estrogen and progesterone to prevent ovulation and in turn pregnancy. However, they do not provide protection against HIV or other sexually transmitted infections. There are two types of hormonal contraceptives available in the market, namely, progestin-only contraceptive and combination hormonal contraceptive. Hormonal contraception acts on the endocrine system to prevent unwanted pregnancy. Synthetic forms of naturally occurring hormones such as progestin and estrogen are used to prevent ovulation and avoid fertilization. These forms of birth control methods also change the environment of uterus, making it unfavorable for fertilization. They are available in a variety of forms such as patches, pill, injection, and rings, which are safe and reliable forms of hormonal contraceptives to prevent pregnancy.

Major factors that drive growth of the global hormonal contraceptive market include rise in focus toward family planning, health issues associated with teenage pregnancies, increase in awareness regarding modern contraception methods, and rise in use of oral pills as a key method to prevent unplanned pregnancy are expected to drive the market growth. In addition, advancements in hormonal contraception with better efficacy and fewer side effects propel the market growth. However, availability of alternate contraceptive methods, health risks associated with use of contraceptives, and lack of social acceptance restricts the market growth.

The global hormonal contraceptive market is segmented on the basis of product, hormone, age group, end user, and region. By product, the market is divided into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, and transdermal patches. On the basis of hormones, it is divided into progestin-only contraceptive and combined hormonal contraceptive. On the basis of age group, it is divided into 15-24 years, 25-34 years, 35-44 years, and above 44 years. By end user, it is divided into hospitals, household, and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA).

The major companies profiled in the report include the Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell LTD., Mayer Laboratories, Merck & Co., Inc., and Church & Dwight, Co., Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis of the current market trends from 2020 to 2023to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to product, hormone type, age group, end user, and region.
  • In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

  • By Product
    • Oral Contraceptive Pills
    • Injectable Birth Control
    • Emergency Contraceptive Pills
    • Vaginal Rings
    • Transdermal Patches
  • By Hormones
    • Progestin-only Contraceptive
    • Combined Hormonal Contraceptive
  • By End User
    • Hospitals
    • Household
    • Clinics
  • By End User
    • 15-24 Years
    • 25-34 Years
    • 35-44 Years
    • Above 44 Years
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA
  • KEY Players
    • the Female Health Company
    • Teva Pharmaceutical Industries Limited
    • Bayer AG, Pfizer, Inc.
    • Mylan N.V.
    • Johnson & Johnson
    • Ansell LTD.
    • Mayer Laboratories
    • Merck & Co., Inc.,
    • Church & Dwight, Co., Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report Description
  • 1.2.Key Market Segments
  • 1.3.Key Benefits
  • 1.4.Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.CXO Perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market Definition and Scope
  • 3.2.Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3.Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4.Market Share Analysis/Top Player Positioning
    • 3.4.1.Market Share Analysis/Top Player Positioning 2020
  • 3.5.Market Dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis

CHAPTER 4:HORMONAL CONTRACEPTIVES MARKET, BY PRODUCT TYPE

  • 4.1.Market Overview
  • 4.1.1Market Size and Forecast, By Product Type
  • 4.2.Oral Contraceptive Pills
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3.Injectable Birth Control
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4.Emergency Contraceptive Pills
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5.Vaginal Rings
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6.Transdermal Patches
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5:HORMONAL CONTRACEPTIVES MARKET, BY HORMONE

  • 5.1.Market Overview
  • 5.1.1Market Size and Forecast, By Hormone
  • 5.2.Progestin Only Contraceptive
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3.Combined Hormonal Contraceptive
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6:HORMONAL CONTRACEPTIVES MARKET, BY AGE GROUP

  • 6.1.Market Overview
  • 6.1.1Market Size and Forecast, By Age Group
  • 6.2.15 To 24 Years
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3.25 To 34 Years
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4.35 To 44 Years
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5.Above 44 Years
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7:HORMONAL CONTRACEPTIVES MARKET, BY END USER

  • 7.1.Market Overview
  • 7.1.1Market Size and Forecast, By End User
  • 7.2.Hospitals
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3.Household
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4.Clinics
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8:HORMONAL CONTRACEPTIVES MARKET, BY REGION

  • 8.1.Market Overview
  • 8.1.1Market Size and Forecast, By Region
  • 8.2.North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Product Type
    • 8.2.3. Market Size and Forecast, By Hormone
    • 8.2.4. Market Size and Forecast, By Age Group
    • 8.2.5. Market Size and Forecast, By End User
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.s. Hormonal Contraceptives Market
      • 8.2.7.1. Market Size and Forecast, By Product Type
      • 8.2.7.2. Market Size and Forecast, By Hormone
      • 8.2.7.3. Market Size and Forecast, By Age Group
      • 8.2.7.4. Market Size and Forecast, By End User
    • 8.2.8. Canada Hormonal Contraceptives Market
      • 8.2.8.1. Market Size and Forecast, By Product Type
      • 8.2.8.2. Market Size and Forecast, By Hormone
      • 8.2.8.3. Market Size and Forecast, By Age Group
      • 8.2.8.4. Market Size and Forecast, By End User
    • 8.2.9. Mexico Hormonal Contraceptives Market
      • 8.2.9.1. Market Size and Forecast, By Product Type
      • 8.2.9.2. Market Size and Forecast, By Hormone
      • 8.2.9.3. Market Size and Forecast, By Age Group
      • 8.2.9.4. Market Size and Forecast, By End User
  • 8.3.Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Product Type
    • 8.3.3. Market Size and Forecast, By Hormone
    • 8.3.4. Market Size and Forecast, By Age Group
    • 8.3.5. Market Size and Forecast, By End User
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Hormonal Contraceptives Market
      • 8.3.7.1. Market Size and Forecast, By Product Type
      • 8.3.7.2. Market Size and Forecast, By Hormone
      • 8.3.7.3. Market Size and Forecast, By Age Group
      • 8.3.7.4. Market Size and Forecast, By End User
    • 8.3.8. France Hormonal Contraceptives Market
      • 8.3.8.1. Market Size and Forecast, By Product Type
      • 8.3.8.2. Market Size and Forecast, By Hormone
      • 8.3.8.3. Market Size and Forecast, By Age Group
      • 8.3.8.4. Market Size and Forecast, By End User
    • 8.3.9. Uk Hormonal Contraceptives Market
      • 8.3.9.1. Market Size and Forecast, By Product Type
      • 8.3.9.2. Market Size and Forecast, By Hormone
      • 8.3.9.3. Market Size and Forecast, By Age Group
      • 8.3.9.4. Market Size and Forecast, By End User
    • 8.3.10. Italy Hormonal Contraceptives Market
      • 8.3.10.1. Market Size and Forecast, By Product Type
      • 8.3.10.2. Market Size and Forecast, By Hormone
      • 8.3.10.3. Market Size and Forecast, By Age Group
      • 8.3.10.4. Market Size and Forecast, By End User
    • 8.3.11. Spain Hormonal Contraceptives Market
      • 8.3.11.1. Market Size and Forecast, By Product Type
      • 8.3.11.2. Market Size and Forecast, By Hormone
      • 8.3.11.3. Market Size and Forecast, By Age Group
      • 8.3.11.4. Market Size and Forecast, By End User
    • 8.3.12. Rest Of Europe Hormonal Contraceptives Market
      • 8.3.12.1. Market Size and Forecast, By Product Type
      • 8.3.12.2. Market Size and Forecast, By Hormone
      • 8.3.12.3. Market Size and Forecast, By Age Group
      • 8.3.12.4. Market Size and Forecast, By End User
  • 8.4.Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Product Type
    • 8.4.3. Market Size and Forecast, By Hormone
    • 8.4.4. Market Size and Forecast, By Age Group
    • 8.4.5. Market Size and Forecast, By End User
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Hormonal Contraceptives Market
      • 8.4.7.1. Market Size and Forecast, By Product Type
      • 8.4.7.2. Market Size and Forecast, By Hormone
      • 8.4.7.3. Market Size and Forecast, By Age Group
      • 8.4.7.4. Market Size and Forecast, By End User
    • 8.4.8. China Hormonal Contraceptives Market
      • 8.4.8.1. Market Size and Forecast, By Product Type
      • 8.4.8.2. Market Size and Forecast, By Hormone
      • 8.4.8.3. Market Size and Forecast, By Age Group
      • 8.4.8.4. Market Size and Forecast, By End User
    • 8.4.9. Australia Hormonal Contraceptives Market
      • 8.4.9.1. Market Size and Forecast, By Product Type
      • 8.4.9.2. Market Size and Forecast, By Hormone
      • 8.4.9.3. Market Size and Forecast, By Age Group
      • 8.4.9.4. Market Size and Forecast, By End User
    • 8.4.10. India Hormonal Contraceptives Market
      • 8.4.10.1. Market Size and Forecast, By Product Type
      • 8.4.10.2. Market Size and Forecast, By Hormone
      • 8.4.10.3. Market Size and Forecast, By Age Group
      • 8.4.10.4. Market Size and Forecast, By End User
    • 8.4.11. South Korea Hormonal Contraceptives Market
      • 8.4.11.1. Market Size and Forecast, By Product Type
      • 8.4.11.2. Market Size and Forecast, By Hormone
      • 8.4.11.3. Market Size and Forecast, By Age Group
      • 8.4.11.4. Market Size and Forecast, By End User
    • 8.4.12. Rest of Asia Pacific Hormonal Contraceptives Market
      • 8.4.12.1. Market Size and Forecast, By Product Type
      • 8.4.12.2. Market Size and Forecast, By Hormone
      • 8.4.12.3. Market Size and Forecast, By Age Group
      • 8.4.12.4. Market Size and Forecast, By End User
  • 8.5.LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Product Type
    • 8.5.3. Market Size and Forecast, By Hormone
    • 8.5.4. Market Size and Forecast, By Age Group
    • 8.5.5. Market Size and Forecast, By End User
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Hormonal Contraceptives Market
      • 8.5.7.1. Market Size and Forecast, By Product Type
      • 8.5.7.2. Market Size and Forecast, By Hormone
      • 8.5.7.3. Market Size and Forecast, By Age Group
      • 8.5.7.4. Market Size and Forecast, By End User
    • 8.5.8. South Africa, Hormonal Contraceptives Market
      • 8.5.8.1. Market Size and Forecast, By Product Type
      • 8.5.8.2. Market Size and Forecast, By Hormone
      • 8.5.8.3. Market Size and Forecast, By Age Group
      • 8.5.8.4. Market Size and Forecast, By End User
    • 8.5.9. Saudi Arabia Hormonal Contraceptives Market
      • 8.5.9.1. Market Size and Forecast, By Product Type
      • 8.5.9.2. Market Size and Forecast, By Hormone
      • 8.5.9.3. Market Size and Forecast, By Age Group
      • 8.5.9.4. Market Size and Forecast, By End User
    • 8.5.10. Rest of LAMEA Hormonal Contraceptives Market
      • 8.5.10.1. Market Size and Forecast, By Product Type
      • 8.5.10.2. Market Size and Forecast, By Hormone
      • 8.5.10.3. Market Size and Forecast, By Age Group
      • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9:COMPANY PROFILES

  • 9.1.Pfizer Inc.
    • 9.1.1.Company Overview
    • 9.1.2.Key Executives
    • 9.1.3.Company snapshot
    • 9.1.4.Operating business segments
    • 9.1.5.Product portfolio
    • 9.1.6.Business Performance
    • 9.1.7.Key Strategic Moves and Developments
  • 9.2.Ansell Limited
    • 9.2.1.Company Overview
    • 9.2.2.Key Executives
    • 9.2.3.Company snapshot
    • 9.2.4.Operating business segments
    • 9.2.5.Product portfolio
    • 9.2.6.Business Performance
    • 9.2.7.Key Strategic Moves and Developments
  • 9.3.Bayer AG
    • 9.3.1.Company Overview
    • 9.3.2.Key Executives
    • 9.3.3.Company snapshot
    • 9.3.4.Operating business segments
    • 9.3.5.Product portfolio
    • 9.3.6.Business Performance
    • 9.3.7.Key Strategic Moves and Developments
  • 9.4.Church And Dwight Co. Inc
    • 9.4.1.Company Overview
    • 9.4.2.Key Executives
    • 9.4.3.Company snapshot
    • 9.4.4.Operating business segments
    • 9.4.5.Product portfolio
    • 9.4.6.Business Performance
    • 9.4.7.Key Strategic Moves and Developments
  • 9.5.Johnson And Johnson
    • 9.5.1.Company Overview
    • 9.5.2.Key Executives
    • 9.5.3.Company snapshot
    • 9.5.4.Operating business segments
    • 9.5.5.Product portfolio
    • 9.5.6.Business Performance
    • 9.5.7.Key Strategic Moves and Developments
  • 9.6.Mayer Laboratories Inc
    • 9.6.1.Company Overview
    • 9.6.2.Key Executives
    • 9.6.3.Company snapshot
    • 9.6.4.Operating business segments
    • 9.6.5.Product portfolio
    • 9.6.6.Business Performance
    • 9.6.7.Key Strategic Moves and Developments
  • 9.7.Merck And Co. Inc
    • 9.7.1.Company Overview
    • 9.7.2.Key Executives
    • 9.7.3.Company snapshot
    • 9.7.4.Operating business segments
    • 9.7.5.Product portfolio
    • 9.7.6.Business Performance
    • 9.7.7.Key Strategic Moves and Developments
  • 9.8.Mylan N.V
    • 9.8.1.Company Overview
    • 9.8.2.Key Executives
    • 9.8.3.Company snapshot
    • 9.8.4.Operating business segments
    • 9.8.5.Product portfolio
    • 9.8.6.Business Performance
    • 9.8.7.Key Strategic Moves and Developments
  • 9.9.Teva Pharmaceutical Industries Ltd
    • 9.9.1.Company Overview
    • 9.9.2.Key Executives
    • 9.9.3.Company snapshot
    • 9.9.4.Operating business segments
    • 9.9.5.Product portfolio
    • 9.9.6.Business Performance
    • 9.9.7.Key Strategic Moves and Developments
  • 9.10.The Female Health Company
    • 9.10.1.Company Overview
    • 9.10.2.Key Executives
    • 9.10.3.Company snapshot
    • 9.10.4.Operating business segments
    • 9.10.5.Product portfolio
    • 9.10.6.Business Performance
    • 9.10.7.Key Strategic Moves and Developments 

LIST OF TABLES

  • TABLE 1.GLOBAL HORMONAL CONTRACEPTIVES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 2.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR ORAL CONTRACEPTIVE PILLS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 3.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR INJECTABLE BIRTH CONTROL, BY REGION, 2020-2030 ($MILLION)
  • TABLE 4.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR EMERGENCY CONTRACEPTIVE PILLS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 5.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR VAGINAL RINGS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 6.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR TRANSDERMAL PATCHES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 7.GLOBAL HORMONAL CONTRACEPTIVES MARKET, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 8.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR PROGESTIN ONLY CONTRACEPTIVE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 9.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR COMBINED HORMONAL CONTRACEPTIVE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.GLOBAL HORMONAL CONTRACEPTIVES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 11.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR 15 TO 24 YEARS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR 25 TO 34 YEARS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR 35 TO 44 YEARS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR ABOVE 44 YEARS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.GLOBAL HORMONAL CONTRACEPTIVES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 16.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR HOUSEHOLD, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.GLOBAL HORMONAL CONTRACEPTIVES MARKET FOR CLINICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.GLOBAL HORMONAL CONTRACEPTIVES MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA HORMONAL CONTRACEPTIVES, BY Region, 2020-2030 ($MILLION)
  • TABLE 21.NORTH AMERICA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 22.NORTH AMERICA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 23.NORTH AMERICA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 24.NORTH AMERICA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 25.U.S. HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 26.U.S. HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 27.U.S. HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 28.U.S. HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 29.CANADA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 30.CANADA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 31.CANADA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 32.CANADA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 33.MEXICO HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 34.MEXICO HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 35.MEXICO HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 36.MEXICO HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 37.EUROPE HORMONAL CONTRACEPTIVES, BY Region, 2020-2030 ($MILLION)
  • TABLE 38.EUROPE HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 39.EUROPE HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 40.EUROPE HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 41.EUROPE HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 42.GERMANY HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 43.GERMANY HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 44.GERMANY HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 45.GERMANY HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 46.FRANCE HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 47.FRANCE HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 48.FRANCE HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 49.FRANCE HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 50.UK HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 51.UK HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 52.UK HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 53.UK HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 54.ITALY HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 55.ITALY HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 56.ITALY HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 57.ITALY HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 58.SPAIN HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 59.SPAIN HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 60.SPAIN HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 61.SPAIN HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 62.REST OF EUROPE HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 63.REST OF EUROPE HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 64.REST OF EUROPE HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 65.REST OF EUROPE HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 66.ASIA-PACIFIC HORMONAL CONTRACEPTIVES, BY Region, 2020-2030 ($MILLION)
  • TABLE 67.ASIA-PACIFIC HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 68.ASIA-PACIFIC HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 69.ASIA-PACIFIC HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 70.ASIA-PACIFIC HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 71.JAPAN HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 72.JAPAN HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 73.JAPAN HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 74.JAPAN HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 75.CHINA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 76.CHINA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 77.CHINA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 78.CHINA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 79.AUSTRALIA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 80.AUSTRALIA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 81.AUSTRALIA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 82.AUSTRALIA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 83.INDIA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 84.INDIA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 85.INDIA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 86.INDIA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 87.SOUTH KOREA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 88.SOUTH KOREA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 89.SOUTH KOREA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 90.SOUTH KOREA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 91.REST OF ASIA PACIFIC HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 92.REST OF ASIA PACIFIC HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 93.REST OF ASIA PACIFIC HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 94.REST OF ASIA PACIFIC HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 95.LAMEA HORMONAL CONTRACEPTIVES, BY Region, 2020-2030 ($MILLION)
  • TABLE 96.LAMEA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 97.LAMEA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 98.LAMEA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 99.LAMEA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 100.BRAZIL HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 101.BRAZIL HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 102.BRAZIL HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 103.BRAZIL HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 104.SOUTH AFRICA, HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 105.SOUTH AFRICA, HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 106.SOUTH AFRICA, HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 107.SOUTH AFRICA, HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 108.SAUDI ARABIA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 109.SAUDI ARABIA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 110.SAUDI ARABIA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 111.SAUDI ARABIA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 112.REST OF LAMEA HORMONAL CONTRACEPTIVES, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 113.REST OF LAMEA HORMONAL CONTRACEPTIVES, BY HORMONE, 2020-2030 ($MILLION)
  • TABLE 114.REST OF LAMEA HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 115.REST OF LAMEA HORMONAL CONTRACEPTIVES, BY END USER, 2020-2030 ($MILLION)
  • TABLE 116.PFIZER INC.: KEY EXECUTIVES
  • TABLE 117.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 118.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 119.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 120.PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121.ANSELL LIMITED: KEY EXECUTIVES
  • TABLE 122.ANSELL LIMITED: COMPANY SNAPSHOT
  • TABLE 123.ANSELL LIMITED: OPERATING SEGMENTS
  • TABLE 124.ANSELL LIMITED: PRODUCT PORTFOLIO
  • TABLE 125.ANSELL LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126.BAYER AG: KEY EXECUTIVES
  • TABLE 127.BAYER AG: COMPANY SNAPSHOT
  • TABLE 128.BAYER AG: OPERATING SEGMENTS
  • TABLE 129.BAYER AG: PRODUCT PORTFOLIO
  • TABLE 130.BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131.CHURCH AND DWIGHT CO. INC: KEY EXECUTIVES
  • TABLE 132.CHURCH AND DWIGHT CO. INC: COMPANY SNAPSHOT
  • TABLE 133.CHURCH AND DWIGHT CO. INC: OPERATING SEGMENTS
  • TABLE 134.CHURCH AND DWIGHT CO. INC: PRODUCT PORTFOLIO
  • TABLE 135.CHURCH AND DWIGHT CO. INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136.JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 137.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 138.JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 139.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 140.JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141.MAYER LABORATORIES INC: KEY EXECUTIVES
  • TABLE 142.MAYER LABORATORIES INC: COMPANY SNAPSHOT
  • TABLE 143.MAYER LABORATORIES INC: OPERATING SEGMENTS
  • TABLE 144.MAYER LABORATORIES INC: PRODUCT PORTFOLIO
  • TABLE 145.MAYER LABORATORIES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146.MERCK AND CO. INC: KEY EXECUTIVES
  • TABLE 147.MERCK AND CO. INC: COMPANY SNAPSHOT
  • TABLE 148.MERCK AND CO. INC: OPERATING SEGMENTS
  • TABLE 149.MERCK AND CO. INC: PRODUCT PORTFOLIO
  • TABLE 150.MERCK AND CO. INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151.MYLAN N.V: KEY EXECUTIVES
  • TABLE 152.MYLAN N.V: COMPANY SNAPSHOT
  • TABLE 153.MYLAN N.V: OPERATING SEGMENTS
  • TABLE 154.MYLAN N.V: PRODUCT PORTFOLIO
  • TABLE 155.MYLAN N.V: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 157.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 158.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
  • TABLE 159.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 160.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161.THE FEMALE HEALTH COMPANY: KEY EXECUTIVES
  • TABLE 162.THE FEMALE HEALTH COMPANY: COMPANY SNAPSHOT
  • TABLE 163.THE FEMALE HEALTH COMPANY: OPERATING SEGMENTS
  • TABLE 164.THE FEMALE HEALTH COMPANY: PRODUCT PORTFOLIO
  • TABLE 165.THE FEMALE HEALTH COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1.GLOBAL HORMONAL CONTRACEPTIVES MARKET SEGMENTATION
  • FIGURE 2.GLOBAL HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 3.SEGMENTATION HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 4.TOP INVESTMENT POCKET IN HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
  • FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
  • FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
  • FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 11.LOW THREAT OF SUBSTITUTION
  • FIGURE 12.HIGH COMPETITIVE RIVALRY
  • FIGURE 13.TOP PLAYER POSITIONING, 2020
  • FIGURE 14.MARKET SHARE ANALYSIS, 2020
  • FIGURE 15.RESTRAINTS AND DRIVERS: HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 16.HORMONAL CONTRACEPTIVES MARKET SEGMENTATION, BY PRODUCT TYPE
  • FIGURE 17.HORMONAL CONTRACEPTIVES MARKET FOR ORAL CONTRACEPTIVE PILLS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 18.HORMONAL CONTRACEPTIVES MARKET FOR INJECTABLE BIRTH CONTROL, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 19.HORMONAL CONTRACEPTIVES MARKET FOR EMERGENCY CONTRACEPTIVE PILLS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 20.HORMONAL CONTRACEPTIVES MARKET FOR VAGINAL RINGS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 21.HORMONAL CONTRACEPTIVES MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 22.HORMONAL CONTRACEPTIVES MARKET SEGMENTATION, BY HORMONE
  • FIGURE 23.HORMONAL CONTRACEPTIVES MARKET FOR PROGESTIN ONLY CONTRACEPTIVE, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 24.HORMONAL CONTRACEPTIVES MARKET FOR COMBINED HORMONAL CONTRACEPTIVE, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 25.HORMONAL CONTRACEPTIVES MARKET SEGMENTATION, BY AGE GROUP
  • FIGURE 26.HORMONAL CONTRACEPTIVES MARKET FOR 15 TO 24 YEARS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 27.HORMONAL CONTRACEPTIVES MARKET FOR 25 TO 34 YEARS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 28.HORMONAL CONTRACEPTIVES MARKET FOR 35 TO 44 YEARS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 29.HORMONAL CONTRACEPTIVES MARKET FOR ABOVE 44 YEARS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 30.HORMONAL CONTRACEPTIVES MARKET SEGMENTATION, BY END USER
  • FIGURE 31.HORMONAL CONTRACEPTIVES MARKET FOR HOSPITALS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 32.HORMONAL CONTRACEPTIVES MARKET FOR HOUSEHOLD, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 33.HORMONAL CONTRACEPTIVES MARKET FOR CLINICS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 34.PFIZER INC.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 36.PFIZER INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 37.ANSELL LIMITED: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 38.ANSELL LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 39.ANSELL LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 40.BAYER AG: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 41.BAYER AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 42.BAYER AG: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 43.CHURCH AND DWIGHT CO. INC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 44.CHURCH AND DWIGHT CO. INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 45.CHURCH AND DWIGHT CO. INC: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 46.JOHNSON AND JOHNSON: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 47.JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 48.JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 49.MAYER LABORATORIES INC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 50.MAYER LABORATORIES INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 51.MAYER LABORATORIES INC: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 52.MERCK AND CO. INC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 53.MERCK AND CO. INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 54.MERCK AND CO. INC: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 55.MYLAN N.V: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 56.MYLAN N.V: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 57.MYLAN N.V: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 58.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 60.TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 61.THE FEMALE HEALTH COMPANY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 62.THE FEMALE HEALTH COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 63.THE FEMALE HEALTH COMPANY: REVENUE SHARE, BY REGION, 2020 (%)